Investigation of the Relationship between MR-Based Supraclavicular Fat Fraction and Thyroid Hormones.
Adults
Brown adipose tissue
Magnetic resonance imaging
Proton density fat fraction
Thyroid hormones
Journal
Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
07
2019
accepted:
13
03
2020
pubmed:
22
6
2020
medline:
23
4
2021
entrez:
22
6
2020
Statut:
ppublish
Résumé
Brown adipose tissue (BAT) plays a potential role in energy and glucose metabolism in humans. Thyroid hormones (TH) are main regulators of BAT development and function. However, it remains unknown how the magnetic resonance (MR)-based proton density fat fraction (PDFF) of supraclavicular adipose tissue used as a surrogate marker for BAT presence relates to TH. Therefore, the purpose of this analysis was to investigate the relationship between supraclavicular PDFF and serum levels of TH. In total, 96 adult volunteers from a large cross-sectional study who underwent additional MR examination of the neck and pelvis were included in this analysis. Segmented PDFF maps of the supraclavicular and gluteal subcutaneous adipose tissue were generated. Delta PDFF was calculated as the difference between gluteal and supraclavicular PDFF and grouped as high (≥12%) or low (<12%) based on the median and the clinical rationale of a high versus low probability of BAT being present. Thyroid-stimulating hormone (mIU/L), free triiodothyronine (FT3, pg/mL) and free thyroxine (FT4, ng/dL) levels were determined in blood samples. Body mass index (BMI) was calculated as weight (kg)/height (m)2. Statistical analyses included the use of paired samples ttest, simple linear regression analysis and a multivariable linear regression analysis. The median age of the subjects (77% female) was 33 years, BMI ranged from 17.2 to 43.1 kg/m2. Supraclavicular and gluteal PDFF differed significantly (76.5 ± 4.8 vs. 89.4 ± 3.5 %, p < 0.01). Supraclavicular PDFF was associated with FT3 in subjects with high delta PDFF (R2 = 0.17, p < 0.01), with higher FT3 being associated with lower supraclavicular PDFF (y = 85.2 + -3.6 x). In a multivariable linear regression analysis considering further potential prognostic factors, the interaction between the delta PDFF group and FT3 remained a predictor for supraclavicular PDFF (B = -4.65, p < 0.01). Supraclavicular PDFF corresponds to the presence of BAT. In the present analysis, supraclavicular PDFF is correlated with FT3 in subjects with high delta PDFF. Therefore, the present findings suggest that biologically active T3 may be involved in the development of supraclavicular BAT.
Identifiants
pubmed: 32564012
pii: 000507294
doi: 10.1159/000507294
pmc: PMC7445585
doi:
Substances chimiques
Thyroid Hormones
0
Thyrotropin
9002-71-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
331-343Informations de copyright
© 2020 The Author(s) Published by S. Karger AG, Basel.
Références
Diabetes. 2009 Jul;58(7):1526-31
pubmed: 19401428
Acad Radiol. 2018 Jan;25(1):102-110
pubmed: 29108812
J Magn Reson Imaging. 2019 Aug;50(2):424-434
pubmed: 30684282
Mol Cell Endocrinol. 2017 Dec 15;458:156-159
pubmed: 28089823
J Nucl Med. 2015 Nov;56(11):1742-7
pubmed: 26272809
J Magn Reson Imaging. 2013 Oct;38(4):885-96
pubmed: 23440739
Cell Metab. 2010 Apr 7;11(4):248-52
pubmed: 20374955
N Engl J Med. 2009 Apr 9;360(15):1509-17
pubmed: 19357406
PLoS One. 2016 May 31;11(5):e0156353
pubmed: 27243823
Contraception. 2003 May;67(5):361-6
pubmed: 12742558
Radiology. 2016 Jul;280(1):4-19
pubmed: 27322970
Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1043-55
pubmed: 25898954
Endocrine. 2018 Nov;62(2):496-500
pubmed: 30066287
J Magn Reson Imaging. 2015 Dec;42(6):1639-45
pubmed: 25914213
Thyroid. 2017 Jan;27(1):1-10
pubmed: 27750020
Endocrinology. 2010 Oct;151(10):5074-83
pubmed: 20719854
Autophagy. 2019 Jan;15(1):131-150
pubmed: 30209975
Endocrinology. 2010 Jan;151(1):432-40
pubmed: 19906816
J Biol Chem. 2002 Jun 14;277(24):21489-98
pubmed: 11940593
Diabetes. 2015 Jul;64(7):2352-60
pubmed: 26050667
J Clin Invest. 2001 Nov;108(9):1379-85
pubmed: 11696583
PLoS One. 2013 Oct 30;8(10):e77907
pubmed: 24205024
Front Endocrinol (Lausanne). 2018 Sep 20;9:556
pubmed: 30294302
J Clin Endocrinol Metab. 1975 Apr;40(4):712-4
pubmed: 805157
NMR Biomed. 2016 Jan;29(1):48-56
pubmed: 26620447
Front Physiol. 2014 Dec 11;5:479
pubmed: 25566082
Magn Reson Med. 2007 Aug;58(2):354-64
pubmed: 17654578
J Magn Reson Imaging. 2017 Sep;46(3):758-768
pubmed: 28092409
Contrast Media Mol Imaging. 2018 Feb 13;2018:4898365
pubmed: 29666563
AJR Am J Roentgenol. 2013 Jan;200(1):177-83
pubmed: 23255760
J Magn Reson Imaging. 2017 Aug;46(2):497-504
pubmed: 28130811
Nuklearmedizin. 2015;54(3):82-7
pubmed: 26105715
Lancet Diabetes Endocrinol. 2013 Nov;1(3):250-8
pubmed: 24622373
PLoS One. 2016 Jan 19;11(1):e0145049
pubmed: 26784028
J Magn Reson Imaging. 2012 Nov;36(5):1011-4
pubmed: 22777847
Exp Physiol. 2003 Jan;88(1):141-8
pubmed: 12525862
Front Endocrinol (Lausanne). 2018 May 23;9:254
pubmed: 29875734
Nat Med. 2013 Oct;19(10):1252-63
pubmed: 24100998
PLoS One. 2015 Apr 30;10(4):e0126705
pubmed: 25928226
Cell Rep. 2013 Dec 12;5(5):1196-203
pubmed: 24290753
Handb Exp Pharmacol. 2019;251:299-324
pubmed: 30099625
J Endocrinol. 2017 Feb;232(2):351-362
pubmed: 27913573
Int J Obes (Lond). 2018 Feb;42(2):175-182
pubmed: 28894290
J Clin Invest. 1987 Jan;79(1):295-300
pubmed: 3793928
Magn Reson Med. 2011 Jan;65(1):96-107
pubmed: 20860006
J Lipid Res. 2008 Sep;49(9):2055-62
pubmed: 18509197
Nat Med. 2011 Feb;17(2):200-5
pubmed: 21258337
Obesity (Silver Spring). 2011 Sep;19(9):1755-60
pubmed: 21566561
J Clin Invest. 2012 Feb;122(2):545-52
pubmed: 22269323
J Clin Endocrinol Metab. 2010 Jan;95(1):256-62
pubmed: 19897683
Diabetes Metab. 2017 Oct;43(5):401-410
pubmed: 28455113
Cell. 2012 Oct 12;151(2):400-13
pubmed: 23063128
Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E444-52
pubmed: 17473055
Sci Rep. 2016 Dec 12;6:38124
pubmed: 27941950
Mol Metab. 2016 Feb 10;5(4):271-282
pubmed: 27069867
Magn Reson Med. 2011 Nov;66(5):1312-26
pubmed: 21452279
Ann Med. 2015 Mar;47(2):133-41
pubmed: 24901355
Crit Rev Biomed Eng. 2015;43(2-3):161-81
pubmed: 27278740
Methods Enzymol. 2014;537:141-59
pubmed: 24480345
Endocrinology. 2010 Sep;151(9):4573-82
pubmed: 20660060
Magn Reson Med. 2017 Nov;78(5):1922-1932
pubmed: 28112821
Diabetes Metab Res Rev. 2014 Sep;30(6):513-20
pubmed: 24823620
Nat Rev Endocrinol. 2014 Jan;10(1):24-36
pubmed: 24146030
Genes Dev. 2012 Feb 1;26(3):271-81
pubmed: 22302939
J Clin Endocrinol Metab. 2014 Jan;99(1):E28-35
pubmed: 24152690